{
  "docId": "019de076-86c0-778c-b811-8ed1a345f3e4",
  "docSlug": "3a23784462a131093cb118313f70597a",
  "documentTitle": "NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides",
  "authorId": "neurobo-pharmaceuticals",
  "authorName": "NeuroBo Pharmaceuticals",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-12-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 24,
  "pageCount": 25,
  "prevPage": 23,
  "nextPage": 25,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 1,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-86c0-778c-b811-8ed1a345f3e4/24",
  "deckHref": "/decks/019de076-86c0-778c-b811-8ed1a345f3e4",
  "deckJsonHref": "/decks/019de076-86c0-778c-b811-8ed1a345f3e4.json",
  "deckAnchorHref": "/decks/019de076-86c0-778c-b811-8ed1a345f3e4#slide-24",
  "components": [
    {
      "bbox": {
        "h": 0.03,
        "w": 0.7,
        "x": 0.076,
        "y": 0.33
      },
      "kind": "list",
      "text": "Aiming to Increase Shareholder Value through Multiple, Near-Term, Value Creating Milestones",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1ed5f3c0-5b84-4da6-85f5-29cd3c214ba0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.7,
        "x": 0.076,
        "y": 0.74
      },
      "kind": "list",
      "text": "Well Capitalized With $25.8 million in Cash at the end of Q3 2023. Cash runway into Q4 2024",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3c0282bb-fbe4-40b6-ae7f-5ed0df430539",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.5,
        "x": 0.09,
        "y": 0.58
      },
      "kind": "list",
      "text": "DA-1726: Submission of IND for Obesity in late December 2023",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7fd40de9-f4ca-4329-ad83-1b2d57faba2b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.5,
        "x": 0.076,
        "y": 0.69
      },
      "kind": "list",
      "text": "Backed by Strategic Partner and Major Shareholder, Dong-A ST",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a1ce6eb0-fa80-48b7-8a39-5b6bff8c7c49",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.5,
        "x": 0.076,
        "y": 0.79
      },
      "kind": "list",
      "text": "Exploring Strategic Opportunities to Out-License legacy assets",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ba975b84-bd84-4a10-99f6-d7185abe4fb7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.7,
        "x": 0.09,
        "y": 0.38
      },
      "kind": "list",
      "text": "DA-1241: Open IND for Treatment of MASH and Type 2 Diabetes; Actively recruiting into a Phase 2a; Completed SAD and MAD studies",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bfa988d1-60a1-4034-a078-4ad86bb41ed3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.8,
        "x": 0.076,
        "y": 0.23
      },
      "kind": "paragraph",
      "text": "Targeting MASH and Obesity with a Pipeline of Next Generation Therapeutics",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "770bc5a6-3d7e-458f-bef8-4fe0e43d5d1c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.57,
        "x": 0.076,
        "y": 0.06
      },
      "kind": "title",
      "text": "Compelling Investment Opportunity",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "472e1a85-55ab-4781-9d86-8d4ec041f9e6",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "8d590f72-d809-42b0-a28f-577a1d10c8e0",
      "evidence": "type: executive_summary",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 24,
      "from": 23,
      "name": "Why Now",
      "slug": "15-why-now",
      "bestFor": "Sales pitches, fundraising, requesting immediate budget approval",
      "matchId": "2d1fd31a-1e17-421e-99fe-ab78f0c7a3f8",
      "evidence": "Slides 23-24 present the investment thesis and compelling opportunity",
      "position": 1,
      "objective": "Why is now the right time to invest in NeuroBo Pharmaceuticals?",
      "structure": "The Context (Trends) -> The Trigger Event -> The Window of Opportunity",
      "confidence": 0.6,
      "description": "Create temporal urgency by proving that the window of opportunity is opening or closing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}